- Home
- IMRN vs BCDA Comparison
IMRN vs BCDA Comparison
Compare IMRN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- BCDA
- Stock Information
- Founded
- IMRN 1994
- BCDA N/A
- Country
- IMRN Australia
- BCDA United States
- Employees
- IMRN N/A
- BCDA N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- BCDA Health Care
- Exchange
- IMRN Nasdaq
- BCDA Nasdaq
- Market Cap
- IMRN 9.2M
- BCDA 10.1M
- IPO Year
- IMRN N/A
- BCDA N/A
- Fundamental
- Price
- IMRN $1.81
- BCDA $1.92
- Analyst Decision
- IMRN Strong Buy
- BCDA Strong Buy
- Analyst Count
- IMRN 1
- BCDA 1
- Target Price
- IMRN $5.00
- BCDA $25.00
- AVG Volume (30 Days)
- IMRN 82.1K
- BCDA 651.7K
- Earning Date
- IMRN 09-08-2025
- BCDA 08-11-2025
- Dividend Yield
- IMRN N/A
- BCDA N/A
- EPS Growth
- IMRN N/A
- BCDA N/A
- EPS
- IMRN N/A
- BCDA N/A
- Revenue
- IMRN $4,048,286.00
- BCDA N/A
- Revenue This Year
- IMRN N/A
- BCDA N/A
- Revenue Next Year
- IMRN N/A
- BCDA N/A
- P/E Ratio
- IMRN N/A
- BCDA N/A
- Revenue Growth
- IMRN 82.90
- BCDA N/A
- 52 Week Low
- IMRN $1.50
- BCDA $1.63
- 52 Week High
- IMRN $2.87
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- IMRN 58.51
- BCDA 44.99
- Support Level
- IMRN $1.62
- BCDA $1.65
- Resistance Level
- IMRN $1.84
- BCDA $1.85
- Average True Range (ATR)
- IMRN 0.09
- BCDA 0.13
- MACD
- IMRN 0.02
- BCDA -0.01
- Stochastic Oscillator
- IMRN 89.55
- BCDA 40.30
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).